Mifepristone (RU486)

Catalog No.S2606 Synonyms: C-1073, RU 38486, Mifegyne

For research use only.

Mifepristone (RU486, C-1073, RU 38486, Mifegyne) is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.

Mifepristone (RU486) Chemical Structure

CAS No. 84371-65-3

Selleck's Mifepristone (RU486) has been cited by 17 publications

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Other Estrogen/progestogen Receptor Products

Biological Activity

Description Mifepristone (RU486, C-1073, RU 38486, Mifegyne) is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.
Features Mifepristone is the first approved medication for patients with endogenous cushing
Targets
Bcl-2 [5]
()
Progesterone receptor [1]
(T47D cells)
Glucocorticoid receptor [1]
(A549 cells)
0.2 nM 2.6 nM
In vitro

Mifepristone inhibit corticoid-induced transcription from a glucocorticoid response element (GRE)-linked luciferase reporter gene in the human lung carcinoma cell line A549. Moreover, Mifepristone also blocks progesterone induction of alkaline phosphatase activity in the human breast cancer cell line T47D. [1] Mifepristone inhibits ovarian cancer cell growth of SK-OV-3 and OV2008 with IC50 of 6.25 μM and 6.91 μM, respectively. [2] A recent study shows that Mifepristone induces caspase-1 over expression both in differentiated and undifferentiated caspase-1-embryonic stem cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO-K1 cells MkDiSpVv[3Srb36gZZN{[Xl? NH\jbXBKdmirYnn0bY9vKG:oIFPIU{1MOSClZXzsd{BmgHC{ZYPzbY5oKGeudXPvZ49zfGmlb3nkJJJm[2WydH;yMEBKSzVyPUjlMVA3KM7:TR?= NXfORmVLOTV2NU[yOFI>
T47D-C124 cells MV3GeY5kfGmxbjDhd5NigQ>? MlHCNlQhcA>? Ml\CRY51[WexbnnzeEBi[3Srdnn0fUBifCCycn;n[ZN1\XKxbnWgdoVk\XC2b4KgbY4hcHWvYX6gWFQ4TC2FMUK0JINmdGy|IITyZY5{\mWldHXkJJdqfGhibIXjbYZmemG|ZTDn[Y5mKGyrbnvl[EB1dyCPTWTWJJBzd22xdHXyJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gdJJw\2W|dHXyc45mNWmwZIXj[YQhdHWlaX\ldoF{\SC2cnHud4FkfGm4YYTpc44h[WO2aY\peJkh[W[2ZYKgNlQhcHK|LDDJR|UxRTJwMXWtNFUh|ryP M1PucFE6OjF4NUS5
neuroblastoma cells MU\GeY5kfGmxbjDhd5NigQ>? MkHHTY4hfmm2cn:gZY51[WexbnnzeEBxd3SnbnP5JIlvKHS{YX7zZYN1cX[jdHnvckBie3OjeTDpckBv\XW{b3LsZZN1d22jIHPlcIx{KGW6cILld5NqdmdiaIXtZY4hWFJvQjDwdo9o\XO2ZYLvcoUhemWlZYD0c5ItKEmFNUC9Nk42\S1yNTFOwG0> MUGxNVE2ODF5Mh?=
T47D cells Mn3uSpVv[3Srb36gZZN{[Xl? NIjpeWI1QCCq MorBRY51[WexbnnzeEBi[3Srdnn0fUBifCCycn;n[ZN1\XKxbnWgdoVk\XC2b4KgbY4hcHWvYX6gWFQ4TCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJBzd2enc4Tldo9v\S2rbnT1Z4VlKGGua3HsbY5mKHCqb4PwbIF1[XOnIHHjeIl3cXS7IHHmeIVzKDR6IHjyd{whUUN3ME20MlVmNTB3IN88US=> M2GyWFE6OjF4NUS5
CV-1 cells NGLqTnZHfW6ldHnvckBie3OjeR?= NYDNNlZJSW62YXfvcol{fGmlIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4heHKxZ3XzeIVzd26nIILlZ4VxfG:{IFKgLIhRWi2EKTDpckBkdy22cnHud4Zm[3SnZDDDWk0yKGOnbHzzMEBKSzVyPUCuNFAxOThizszN Ml\UPVQ5PDVzMR?=
HEK293 cells MUDGeY5kfGmxbjDhd5NigQ>? MoTvRY51[WexbnnzeEBi[3Srdnn0fUBi\2GrboP0JIdtfWOxY3;yeIlkd2mmIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDHVmUu\GWyZX7k[Y51KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OD1yLkCwNFI6QCEQvF2= M4XWTFI3OjF6M{Sz
COS7 cells MlTxSpVv[3Srb36gZZN{[Xl? NHLJUJJCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHPsc45m\CCpbIXjc4NwenSrY3;p[EBz\WOncITvdk1tcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEORU{egZ4VtdHNiYomgS2FNPCCudXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwQVAvODByNjFOwG0> NWizcWZ4OTh3MESxN|I>
SW1353 cells NES1UopHfW6ldHnvckBie3OjeR?= M{S2ZmJqdmSrbnegZYZncW6rdImgeI8h\2y3Y3;jc5J1cWOxaXSgdoVk\XC2b4KgbY4hW1dzM{WzJINmdGy|IHL5JJdpd2ynLXPlcIwh[mmwZHnu[{Bie3OjeTygT4k:OC5yMEC4NkDPxE1? MlnpNVc5OjJ6OUe=
A549 cells M3LlcGZ2dmO2aX;uJIF{e2G7 MYXBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIdtfWOxY3;yeIlkd2mmIILlZ4VxfG:{IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3;yeIlkd2mmLXnu[JVk\WRidILhcpNkemmydHnvckBqdiCqdX3hckBCPTR7IHPlcIx{KGK7IFfSSU1tcW6tZXSgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> NULpPJB1OTd|MUexOlc>
A549 cells NVXJV2k1TnWwY4Tpc44h[XO|YYm= NX7QdpFDOTZiaB?= MofVRY51[WexbnnzeEBi[3Srdnn0fUBifCCpbIXjc4NwenSrY3;p[EBz\WOncITvdkBqdiCqdX3hckBCPTR7IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2:{dHnjc4llNWmwZIXj[YQhfHKjboPjdolxfGmxbjDh[pRmeiBzNjDodpMh[nliZ3z1Z49kd3K2aXPvbYQhemW|cH;ud4Uh\WynbXXueE1lemm4ZX6gcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> MnPyNVkzOTd{OEW=
rat H4-IIE cells M4DQNWZ2dmO2aX;uJIF{e2G7 M2LtUFEhcA>? NEPNe5dCdnSjZ3;ubZN1KGGldHn2bZR6KGGpYXnud5Qh\2y3Y3;jc5J1cWOxaXSgdoVk\XC2b4KgbY4hemG2IFi0MWlKTSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIRmgGGvZYToZZNwdmVvaX7keYNm\CC{ZXPldJRweiC2cnHud4FkfGm4YYTpc44heHKnLXnuZ5Vj[XSnZDDmc5IhOSCqcjDi[YZwemViZHX4ZY1mfGijc3;u[UBi\GSrdHnvckBidmRibXXhd5Vz\WRiMkSgbJJ{KHCxc4Sg[IV5[W2ndHjhd49v\SC|dHnteYxifGmxbjDifUB1gXKxc3nu[UBidWmwb4TyZY5{\mW{YYPlJIVvgnmvZTDhd5NigSxiSVO1NF0xNjByMUm0JO69VQ>? M3WySlI3OjF6M{Sz
HeLa cells MkLGSpVv[3Srb36gZZN{[Xl? MWfF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCjZ3HpcpN1KGmwaHnibZRqd25ib3[gSIV5[W2ndHjhd49v\SCrbnT1Z4VlKGeudXPvZ49zfGmlb3nkJJJm[2WydH;yJJRz[W6|YXP0bZZifGmxbjDv[kBud3W|ZTDtZY1u[XK7IIT1cY9zKH[rcoXzJIx2[2moZYLhd4Uh\2WwZTDpckBJ\UyjIHPlcIx{NCCHQ{WwQVAvODB{IN88US=> NHXjPVQyPjFzMkW3NS=>
NIH3T3 cells MWLGeY5kfGmxbjDhd5NigQ>? NXnCTGZzUW5idnn0do8h[W62YXfvcol{fCCyb4TlcoN6KGmwIITyZY5{[WO2aY\heIlwdiCjc4PhfUBqdiCQSVizWFMh[2WubIOg[ZhxemW|c3nu[{BodHWlb3PvdpRq[2:rZDDy[YNmeHSxcjygTWM2OD1yLkCwNlIh|ryP M4PQRlEyOTVyMUey
CHO cells MU\GeY5kfGmxbjDhd5NigQ>? M4HpfWlvcGmkaYTpc44hd2ZiRHX4ZY1mfGijc3;u[UB{fGmvdXzheIVlKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBqdiCFSF:gZ4VtdHNiZYjwdoV{e2mwZzDncJVkd2OxcoTpZ49q\CC{ZXPldJRweixiSVO1NF0xNjByNTFOwG0> M{fGTVEzQDJ2MEKz
hGRAF cells NFvTfmZHfW6ldHnvckBie3OjeR?= MnPzTY5pcWKrdHnvckBw\iCqdX3hckBIWiCneIDy[ZN{\WRiaX6gbGdTSUZiY3XscJMtKEurPUCuNFA2KM7:TR?= MXyxO|A4ODB2Nx?=
COS-1 NITaNZNHfW6ldHnvckBie3OjeR?= M2DM[GJqdmSrbnegZYZncW6rdImg[o9zKGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIlvKHS{YX7zbYVvfGy7LYTyZY5{\mWldHXkJGNQWy1zIHPlcIx{NCCNaU2wMlAzOiEQvF2= MVO5OFg1PTFz
rat hepatocytes NXrxbJU3TnWwY4Tpc44h[XO|YYm= NFu4O5lKdmirYnn0bY9vKG:oIHTlfIFu\XSqYYPvcoUucW6mdXPl[EBIWi2vZXTpZZRm\CC2eYLvd4lv\SCjbXnuc{B1emGwc3\ldoF{\SCjY4Tpeol1gSCrbjDyZZQhcGWyYYTvZ5l1\XNuIFnDOVA:OC5{NzFOwG0> MoT4NVUzPjF{Nk[=
human K562/R7 cells M{fRbGZ2dmO2aX;uJIF{e2G7 M3zaSFczKGh? MVzQc5RmdnSrYYTpc44hd2ZiZH;4c5J2[mmlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBld3ixcoXibYNqdi2{ZYPpd5RidnRiaIXtZY4hUzV4Mj;SO{Bk\WyuczDhd5Nme3OnZDDhd{Bld3ixcoXibYNqdiCLQ{WwJIF1KDFidV2gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkmg{txO MViyOVY{PDB2MR?=
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-ERK / ERK ; MMP-2 / MMP-9 / COX-2 / VEGF 28938623
In vivo

Mifepristone can impair the growth of SK-OV-3 tumors in immunosuppressed mice at 0.5 mg/day and 1 mg/day. [2] Mifepristone inhibits the prostate weight significantly in the highest doses in vivo, and inhibits growth of the prostate gland produced by dihydrotestosterone (DHT) to a greater extent than the induction of atrophy and cell death in rats. [4]

Protocol (from reference)

Kinase Assay:

[1]

  • Glucocorticoid receptor (GR) antagonist activity, Progesterone receptor (PR) antagonist activity:

    T47D alkaline phosphatase assay: T47D human breast cancer cells are plated in 96-well tissue culture plates at 104 cells per well in assay medium [RPMI medium without phenol red containing 5% (v/v) charcoal-treated FBS and 1% (v/v) penicillin–streptomycin]. Two days later, the medium is decanted and Mifepristone or control is added at a final concentration of 0.1% (v/v) dimethylsulfoxide in fresh assay medium. Twenty-four hours later, an alkaline phosphatase assay is performed using a SEAP kit. The medium is decanted and the cells are fixed for 30 minutes at room temperature with 5% (v/v) formalin. The cells are washed once at room temperature with Hanks

Cell Research:

[2]

  • Cell lines: OV2008 and SK-OV-3 cells
  • Concentrations: 0-20 μM
  • Incubation Time: 24 hours
  • Method:

    Cell growth is evaluated in various ovarian cancer cell lines that are subjected to dose-response or time course treatments. Media containing each of the doses of fresh steroids is replaced every 24 hours. Control groups of cells are treated with vehicle ethanol at a final concentration of less than 0.05%. Number of viable cells is evaluated by trypsinization and counting in a hemocytometer chamber using trypan blue dye exclusion. Experiments are conducted in media without phenol red and supplemented with charcoal extracted fetal bovine serum, or media containing unextracted serum and having phenol red. Similar results are obtained with both media preparations; therefore, after performing the growth curves, all subsequent experiments are conducted using media with unextracted serum and in the presence of phenol red. When indicated, the proliferation IC50s are calculated using software designed to study drug interaction.

  • (Only for Reference)
Animal Research:

[2]

  • Animal Models: SK-OV-3 ovarian cancer cells are injected into immunosuppressed mice.
  • Dosages: 0.5 or 1 mg/day
  • Administration: Implanted s.c. with pellets
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 85 mg/mL
(197.86 mM)
Water Insoluble
Ethanol ''''19 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 429.59
Formula

C29H35NO2

CAS No. 84371-65-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04905251 Not yet recruiting Drug: Mifepristone-Misoprostol Medical Abortion Linepharma International LTD December 31 2021 --
NCT05062174 Not yet recruiting Drug: Mifepristone 200 MG|Procedure: Prophylactic mastectomy BRCA1 Mutation|High-grade Serous Ovarian Cancer|TNBC - Triple-Negative Breast Cancer Indiana University|Breast Cancer Research Foundation October 1 2021 --
NCT03258372 Completed Drug: Mifepristone Healthy Corcept Therapeutics August 16 2017 Phase 1
NCT03259542 Completed Drug: Mifepristone 300 MG|Drug: Itraconazole 100 MG Drug Interaction Potentiation|Healthy Corcept Therapeutics August 9 2017 Phase 1
NCT02985229 Completed Drug: Mifepristone|Drug: Misoprostol Medical Abortion Gynuity Health Projects October 2016 Phase 3
NCT02745093 Unknown status Drug: Mifepristone|Drug: Misoprostol Medical Abortion Ibis Reproductive Health|Marie Stopes International September 2016 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Mifepristone (RU486) | Mifepristone (RU486) ic50 | Mifepristone (RU486) price | Mifepristone (RU486) cost | Mifepristone (RU486) solubility dmso | Mifepristone (RU486) purchase | Mifepristone (RU486) manufacturer | Mifepristone (RU486) research buy | Mifepristone (RU486) order | Mifepristone (RU486) mouse | Mifepristone (RU486) chemical structure | Mifepristone (RU486) mw | Mifepristone (RU486) molecular weight | Mifepristone (RU486) datasheet | Mifepristone (RU486) supplier | Mifepristone (RU486) in vitro | Mifepristone (RU486) cell line | Mifepristone (RU486) concentration | Mifepristone (RU486) nmr